Vutrisiran Global Market Report 2025

Vutrisiran Global Market Report 2025 - By Drug Class (Antisense Oligonucleotide, Nucleic Acids, Nucleotide, Nucleoside, Other Drug Classes), By Route Of Administration (Oral, Injectable, Subcutaneous), By Patient Demographics (Pediatric, Adult, Geriatric), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channels) - Market Size, Trends, And Global Forecast 2025-2034

Name: Vutrisiran Global Market Report 2025
Creator: The Business Research Company
License: https://www.thebusinessresearchcompany.com/privacy-policy

Vutrisiran Global Market Report 2025

Report Price : $4490.00 | Pages : 175 | Published : March 2025 | Delivery Time: 2-3 business days | Format : pdf

Purchase Options

Request a Sample

Request For Discount

Customise Your Report

Item added to cart!

Request For Proposal

Request For Regional Data

FAQs

Need assistance or more information before the purchase?

Enquire Before Buying

Proud Members Of

What Is Covered Under Vutrisiran Market

Vutrisiran is a small interfering RNA (siRNA) therapy for hereditary transthyretin-mediated (hATTR) amyloidosis. It silences the transthyretin (TTR) gene, reducing abnormal TTR protein deposits that cause polyneuropathy and organ damage. Vutrisiran helps slow disease progression and improve neurological function, mobility, and quality of life with a longer dosing interval.

The main types of drug classes for the vutrisiran are antisense oligonucleotide, nucleic acids, nucleotides, nucleosides, and others. Antisense oligonucleotides (ASOs) are synthetic short DNA or RNA molecules that target specific mRNA sequences to regulate gene expression. It is administered through various routes of administration, such as oral, injectable, and subcutaneous, for several patient demographics, including Pediatric, adult, and geriatric. It is distributed through various distribution channels such as hospital pharmacies, retail pharmacies, online pharmacies, and others.

How Is The Vutrisiran Market Segmented?

The vutrisiran market covered in this report is segmented –

1) By Drug Class: Antisense Oligonucleotide, Nucleic Acids, Nucleotide, Nucleoside, Other Drug Classes

2) By Route Of Administration: Oral, Injectable, Subcutaneous

3) By Patient Demographics: Pediatric, Adult, Geriatric

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channels

Subsegments:

1) By Antisense Oligonucleotide: Single-Stranded Antisense Oligonucleotides, Double-Stranded Antisense Oligonucleotides

2) By Nucleic Acids: DNA-based Nucleic Acids, RNA-based Nucleic Acids

3) By Nucleotide: Purine Nucleotides, Pyrimidine Nucleotides

4) By Nucleoside: Purine Nucleosides, Pyrimidine Nucleosides

5) By Other Drug Classes: Peptide-Based Drugs, Protein Therapeutics

Vutrisiran Market Size and growth rate 2025 to 2029: Graph

What Is The Vutrisiran Market Size 2025 And Growth Rate?

The vutrisiran market size has grown rapidly in recent years. It will grow from $0.60 billion in 2024 to $0.68 billion in 2025 at a compound annual growth rate (CAGR) of 12.8%. The growth in the historic period can be attributed to increasing awareness of hereditary transthyretin amyloidosis, rising clinical trials, increasing healthcare spending, rising patient preference for non-invasive administration methods, and rising genetic disorders.

What Is The Vutrisiran Market Growth Forecast?

The vutrisiran market size is expected to see rapid growth in the next few years. It will grow to $1.08 billion in 2029 at a compound annual growth rate (CAGR) of 12.4%. The growth in the forecast period can be attributed to increasing healthcare availability, rising prevalence of chronic diseases, increasing investment in research and development, growing focus on personalized medicine, and rising awareness of disease. Major trends in the forecast period include development in combination therapy, adoption of targeted therapy, advancement in personalized medicine, development in digital health technologies, and advancements in biotechnology.

Book your 30 minutes free consultation with our research experts

What Is Driving The Vutrisiran Market: Rising Research And Development (R&D) Investments Fuel Growth Of The Market

The increasing investment in research and development is expected to propel the growth of the vutrisiran market going forward. Research and development refers to innovating and improving products, services, or processes through systematic investigation and experimentation. The increasing investment in research and development (R&D)is due to government initiatives and funding, growing healthcare and pharmaceutical needs, sustainability, and environmental concerns. Research and development funding allows pharmaceutical companies to conduct clinical trials, demonstrating the drug's long-term benefits and safety, leading to broader regulatory approvals. Additionally, RNA interference (RNAi) technology advancements improve the drug's precision, reducing side effects and increasing patient adoption. For instance, in December 2023, according to Eurostat, a Luxembourg-based statistical office of the European Union, in 2022, the European Union's expenditure on research and development (R&D) increased to €352 billion ($384.42 billion), marking a 6.34% rise from €331 billion ($361.48 billion) in the previous year. Therefore, the increasing investment in research and development is driving the growth of the vutrisiran

Who Are The Major Players In The Global Vutrisiran Market?

Major companies operating in the vutrisiran market are Alnylam Pharmaceuticals Inc

What Are The Key Trends Of The Global Vutrisiran Market: Advancements In Subcutaneous RNAi Therapeutics For hATTR Amyloidosis Treatment

The key trend in the vutrisiran market is focusing on developing innovative therapeutics, such as subcutaneous RNAi therapeutics, to provide more convenient, less frequent dosing options for the management of hereditary transthyretin-mediated (hATTR) amyloidosis. Subcutaneous RNAi therapeutics are treatments that use RNA interference technology, administered via injection under the skin, designed for sustained release. This method ensures consistent drug levels over time, improving patient convenience and adherence in treating polyneuropathy associated with hereditary transthyretin-mediated (hATTR) amyloidosis. For instance, in June 2022, Alnylam Pharmaceuticals, a US-based biopharmaceutical company, announced that vutrisiran (AMVUTTRA) was approved by the Food and Drug Administration (FDA). It is used for the treatment of polyneuropathy in adults with hereditary transthyretin-mediated (hATTR) amyloidosis. It significantly improves neuropathy symptoms and halts disease progression. In the HELIOS-A Phase 3 study, over 50% of patients experienced a reversal or halt of disease manifestations. AMVUTTRA offers a promising safety profile, with no drug-related discontinuations or deaths, and a dosing regimen that may improve patient compliance.

What Are Latest Mergers And Acquisitions In The Vutrisiran Market: Medison Pharma Expands Partnership With Alnylam Pharmaceuticals To Enhance Global Access To RNAi Therapies

In April 2024, Medison Pharma, an Israel-based pharmaceutical company, partnered with Alnylam Pharmaceuticals Inc. to expand the commercialization of RNAi therapeutics. The partnership aims to enhance global access to Alnylam's groundbreaking RNAi therapies, especially for patients with rare diseases, by utilizing Medison's integrated commercialization platform across various regions, including LATAM, APAC, and other international markets. Alnylam Pharmaceuticals, Inc. is a US-based pharmaceutical company that manufactures vutrisiran.

What Is The Regional Outlook For The Global Vutrisiran Market?

North America was the largest region in the vutrisiran market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the vutrisiran market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the vutrisiran market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Vutrisiran Market?

The vutrisiran market consists of sales of pre-filled syringes and vials for subcutaneous injection. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What is the Market Assessment and Strategic Outlook for the Vutrisiran Industry?

The vutrisiran market research report is one of a series of new reports from The Business Research Company that provides vutrisiran market statistics, including the vutrisiran industry global market size, regional shares, competitors with the vutrisiran market share, detailed vutrisiran market segments, market trends, and opportunities, and any further data you may need to thrive in the vutrisiran industry. This vutrisiran market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

Vutrisiran Market Report Forecast Analysis

Report Attribute	Details
Market Size Value In 2025	$0.68 billion
Revenue Forecast In 2034	$1.08 billion
Growth Rate	CAGR of 12.4% from 2025 to 2034
Base Year For Estimation	2024
Actual Estimates/Historical Data	2019-2024
Forecast Period	2025 - 2029 - 2034
Market Representation	Revenue in USD Billion and CAGR from 2025 to 2034
Segments Covered	The vutrisiran market covered in this report is segmented – 1) By Drug Class: Antisense Oligonucleotide, Nucleic Acids, Nucleotide, Nucleoside, Other Drug Classes 2) By Route Of Administration: Oral, Injectable, Subcutaneous 3) By Patient Demographics: Pediatric, Adult, Geriatric 4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channels Subsegments: 1) By Antisense Oligonucleotide: Single-Stranded Antisense Oligonucleotides, Double-Stranded Antisense Oligonucleotides 2) By Nucleic Acids: DNA-based Nucleic Acids, RNA-based Nucleic Acids 3) By Nucleotide: Purine Nucleotides, Pyrimidine Nucleotides 4) By Nucleoside: Purine Nucleosides, Pyrimidine Nucleosides 5) By Other Drug Classes: Peptide-Based Drugs, Protein Therapeutics
Regional Scope	Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Country Scope	The countries covered in the report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain. Additional countries that can be covered in the report are Bangladesh, Thailand, Vietnam, Malaysia, Singapore, Philippines, Hong Kong, New Zealand, Mexico, Chile, Argentina, Colombia, Peru, Austria, Belgium, Denmark, Finland, Ireland, Netherlands, Norway, Portugal, Sweden, Switzerland, Czech Republic, Poland, Romania, Ukraine, Saudi Arabia, Israel, Iran, Turkey, UAE, Egypt, Nigeria, South Africa.
Key Companies Profiled	Alnylam Pharmaceuticals Inc
Customization Scope	Request for Sample
Pricing And Purchase Options	Explore Purchase Options

1. Executive Summary

2. Vutrisiran Market Characteristics

3. Vutrisiran Market Trends And Strategies

4. Vutrisiran Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Vutrisiran Growth Analysis And Strategic Analysis Framework

5.1. Global Vutrisiran PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)

5.2. Analysis Of End Use Industries

5.3. Global Vutrisiran Market Growth Rate Analysis

5.4. Global Vutrisiran Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)

5.5. Global Vutrisiran Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)

5.6. Global Vutrisiran Total Addressable Market (TAM)

6. Vutrisiran Market Segmentation

6.1. Global Vutrisiran Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Antisense Oligonucleotide

Nucleic Acids

Nucleotide

Nucleoside

Other Drug Classes

6.2. Global Vutrisiran Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Oral

Injectable

Subcutaneous

6.3. Global Vutrisiran Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Pediatric

Adult

Geriatric

6.4. Global Vutrisiran Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Other Distribution Channels

6.5. Global Vutrisiran Market, Sub-Segmentation Of Antisense Oligonucleotide, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Single-Stranded Antisense Oligonucleotides

Double-Stranded Antisense Oligonucleotides

6.6. Global Vutrisiran Market, Sub-Segmentation Of Nucleic Acids, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

DNA-based Nucleic Acids

RNA-based Nucleic Acids

6.7. Global Vutrisiran Market, Sub-Segmentation Of Nucleotide, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Purine Nucleotides

Pyrimidine Nucleotides

6.8. Global Vutrisiran Market, Sub-Segmentation Of Nucleoside, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Purine Nucleosides

Pyrimidine Nucleosides

6.9. Global Vutrisiran Market, Sub-Segmentation Of Other Drug Classes, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Peptide-Based Drugs

Protein Therapeutics

7. Vutrisiran Market Regional And Country Analysis

7.1. Global Vutrisiran Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

7.2. Global Vutrisiran Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Vutrisiran Market

8.1. Asia-Pacific Vutrisiran Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

8.2. Asia-Pacific Vutrisiran Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8.3. Asia-Pacific Vutrisiran Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8.4. Asia-Pacific Vutrisiran Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Vutrisiran Market

9.1. China Vutrisiran Market Overview

9.2. China Vutrisiran Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

9.3. China Vutrisiran Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

9.4. China Vutrisiran Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Vutrisiran Market

10.1. India Vutrisiran Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

10.2. India Vutrisiran Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

10.3. India Vutrisiran Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Vutrisiran Market

11.1. Japan Vutrisiran Market Overview

11.2. Japan Vutrisiran Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11.3. Japan Vutrisiran Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11.4. Japan Vutrisiran Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Vutrisiran Market

12.1. Australia Vutrisiran Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12.2. Australia Vutrisiran Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12.3. Australia Vutrisiran Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Vutrisiran Market

13.1. Indonesia Vutrisiran Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13.2. Indonesia Vutrisiran Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13.3. Indonesia Vutrisiran Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Vutrisiran Market

14.1. South Korea Vutrisiran Market Overview

14.2. South Korea Vutrisiran Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14.3. South Korea Vutrisiran Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14.4. South Korea Vutrisiran Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Vutrisiran Market

15.1. Western Europe Vutrisiran Market Overview

15.2. Western Europe Vutrisiran Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15.3. Western Europe Vutrisiran Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15.4. Western Europe Vutrisiran Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Vutrisiran Market

16.1. UK Vutrisiran Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16.2. UK Vutrisiran Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16.3. UK Vutrisiran Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Vutrisiran Market

17.1. Germany Vutrisiran Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17.2. Germany Vutrisiran Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17.3. Germany Vutrisiran Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Vutrisiran Market

18.1. France Vutrisiran Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18.2. France Vutrisiran Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18.3. France Vutrisiran Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Vutrisiran Market

19.1. Italy Vutrisiran Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19.2. Italy Vutrisiran Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19.3. Italy Vutrisiran Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Vutrisiran Market

20.1. Spain Vutrisiran Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20.2. Spain Vutrisiran Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20.3. Spain Vutrisiran Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Vutrisiran Market

21.1. Eastern Europe Vutrisiran Market Overview

21.2. Eastern Europe Vutrisiran Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21.3. Eastern Europe Vutrisiran Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21.4. Eastern Europe Vutrisiran Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Vutrisiran Market

22.1. Russia Vutrisiran Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22.2. Russia Vutrisiran Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22.3. Russia Vutrisiran Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Vutrisiran Market

23.1. North America Vutrisiran Market Overview

23.2. North America Vutrisiran Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23.3. North America Vutrisiran Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23.4. North America Vutrisiran Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Vutrisiran Market

24.1. USA Vutrisiran Market Overview

24.2. USA Vutrisiran Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24.3. USA Vutrisiran Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24.4. USA Vutrisiran Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Vutrisiran Market

25.1. Canada Vutrisiran Market Overview

25.2. Canada Vutrisiran Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25.3. Canada Vutrisiran Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25.4. Canada Vutrisiran Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Vutrisiran Market

26.1. South America Vutrisiran Market Overview

26.2. South America Vutrisiran Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26.3. South America Vutrisiran Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26.4. South America Vutrisiran Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Vutrisiran Market

27.1. Brazil Vutrisiran Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27.2. Brazil Vutrisiran Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27.3. Brazil Vutrisiran Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Vutrisiran Market

28.1. Middle East Vutrisiran Market Overview

28.2. Middle East Vutrisiran Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28.3. Middle East Vutrisiran Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28.4. Middle East Vutrisiran Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Vutrisiran Market

29.1. Africa Vutrisiran Market Overview

29.2. Africa Vutrisiran Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29.3. Africa Vutrisiran Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29.4. Africa Vutrisiran Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Vutrisiran Market Competitive Landscape And Company Profiles

30.1. Vutrisiran Market Competitive Landscape

30.2. Vutrisiran Market Company Profiles

30.2.1. Alnylam Pharmaceuticals Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Global Vutrisiran Market Competitive Benchmarking And Dashboard

32. Key Mergers And Acquisitions In The Vutrisiran Market

33. Recent Developments In The Vutrisiran Market

34. Vutrisiran Market High Potential Countries, Segments and Strategies

34.1 Vutrisiran Market In 2029 - Countries Offering Most New Opportunities

34.2 Vutrisiran Market In 2029 - Segments Offering Most New Opportunities

34.3 Vutrisiran Market In 2029 - Growth Strategies

34.3.1 Market Trend Based Strategies

34.3.2 Competitor Strategies

35. Appendix

35.1. Abbreviations

35.2. Currencies

35.3. Historic And Forecast Inflation Rates

35.4. Research Inquiries

35.5. The Business Research Company

35.6. Copyright And Disclaimer

List Of Tables

Table 1: Global Historic Market Growth, 2019-2024, $ Billion

Table 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion

Table 3: Global Vutrisiran Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 4: Global Vutrisiran Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 5: Global Vutrisiran Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 6: Global Vutrisiran Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 7: Global Vutrisiran Market, Sub-Segmentation Of Antisense Oligonucleotide, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 8: Global Vutrisiran Market, Sub-Segmentation Of Nucleic Acids, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 9: Global Vutrisiran Market, Sub-Segmentation Of Nucleotide, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 10: Global Vutrisiran Market, Sub-Segmentation Of Nucleoside, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 11: Global Vutrisiran Market, Sub-Segmentation Of Other Drug Classes, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 12: Global Vutrisiran Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 13: Global Vutrisiran Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 14: Asia-Pacific, Vutrisiran Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 15: Asia-Pacific, Vutrisiran Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 16: Asia-Pacific, Vutrisiran Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 17: China, Vutrisiran Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 18: China, Vutrisiran Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 19: China, Vutrisiran Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 20: India, Vutrisiran Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 21: India, Vutrisiran Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 22: India, Vutrisiran Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 23: Japan, Vutrisiran Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 24: Japan, Vutrisiran Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 25: Japan, Vutrisiran Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 26: Australia, Vutrisiran Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 27: Australia, Vutrisiran Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 28: Australia, Vutrisiran Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 29: Indonesia, Vutrisiran Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 30: Indonesia, Vutrisiran Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 31: Indonesia, Vutrisiran Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 32: South Korea, Vutrisiran Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 33: South Korea, Vutrisiran Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 34: South Korea, Vutrisiran Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 35: Western Europe, Vutrisiran Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 36: Western Europe, Vutrisiran Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 37: Western Europe, Vutrisiran Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 38: UK, Vutrisiran Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 39: UK, Vutrisiran Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 40: UK, Vutrisiran Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 41: Germany, Vutrisiran Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 42: Germany, Vutrisiran Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 43: Germany, Vutrisiran Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 44: France, Vutrisiran Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 45: France, Vutrisiran Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 46: France, Vutrisiran Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 47: Italy, Vutrisiran Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 48: Italy, Vutrisiran Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 49: Italy, Vutrisiran Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 50: Spain, Vutrisiran Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 51: Spain, Vutrisiran Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 52: Spain, Vutrisiran Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 53: Eastern Europe, Vutrisiran Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 54: Eastern Europe, Vutrisiran Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 55: Eastern Europe, Vutrisiran Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 56: Russia, Vutrisiran Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 57: Russia, Vutrisiran Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 58: Russia, Vutrisiran Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 59: North America, Vutrisiran Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 60: North America, Vutrisiran Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 61: North America, Vutrisiran Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 62: USA, Vutrisiran Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 63: USA, Vutrisiran Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 64: USA, Vutrisiran Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 65: Canada, Vutrisiran Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 66: Canada, Vutrisiran Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 67: Canada, Vutrisiran Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 68: South America, Vutrisiran Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 69: South America, Vutrisiran Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 70: South America, Vutrisiran Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 71: Brazil, Vutrisiran Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 72: Brazil, Vutrisiran Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 73: Brazil, Vutrisiran Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 74: Middle East, Vutrisiran Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 75: Middle East, Vutrisiran Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 76: Middle East, Vutrisiran Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 77: Africa, Vutrisiran Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 78: Africa, Vutrisiran Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 79: Africa, Vutrisiran Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 80: Alnylam Pharmaceuticals Inc. Financial Performance

List Of Figures

Figure 1: Global Historic Market Growth, 2019-2024, $ Billion

Figure 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion

Figure 3: Global Vutrisiran Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 4: Global Vutrisiran Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 5: Global Vutrisiran Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 6: Global Vutrisiran Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 7: Global Vutrisiran Market, Sub-Segmentation Of Antisense Oligonucleotide, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 8: Global Vutrisiran Market, Sub-Segmentation Of Nucleic Acids, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 9: Global Vutrisiran Market, Sub-Segmentation Of Nucleotide, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 10: Global Vutrisiran Market, Sub-Segmentation Of Nucleoside, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 11: Global Vutrisiran Market, Sub-Segmentation Of Other Drug Classes, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 12: Global Vutrisiran Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 13: Global Vutrisiran Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 14: Asia-Pacific, Vutrisiran Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 15: Asia-Pacific, Vutrisiran Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 16: Asia-Pacific, Vutrisiran Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 17: China, Vutrisiran Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 18: China, Vutrisiran Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 19: China, Vutrisiran Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 20: India, Vutrisiran Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 21: India, Vutrisiran Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 22: India, Vutrisiran Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 23: Japan, Vutrisiran Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 24: Japan, Vutrisiran Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 25: Japan, Vutrisiran Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 26: Australia, Vutrisiran Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 27: Australia, Vutrisiran Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 28: Australia, Vutrisiran Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 29: Indonesia, Vutrisiran Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 30: Indonesia, Vutrisiran Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 31: Indonesia, Vutrisiran Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 32: South Korea, Vutrisiran Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 33: South Korea, Vutrisiran Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 34: South Korea, Vutrisiran Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 35: Western Europe, Vutrisiran Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 36: Western Europe, Vutrisiran Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 37: Western Europe, Vutrisiran Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 38: UK, Vutrisiran Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 39: UK, Vutrisiran Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 40: UK, Vutrisiran Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 41: Germany, Vutrisiran Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 42: Germany, Vutrisiran Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 43: Germany, Vutrisiran Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 44: France, Vutrisiran Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 45: France, Vutrisiran Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 46: France, Vutrisiran Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 47: Italy, Vutrisiran Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 48: Italy, Vutrisiran Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 49: Italy, Vutrisiran Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 50: Spain, Vutrisiran Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 51: Spain, Vutrisiran Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 52: Spain, Vutrisiran Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 53: Eastern Europe, Vutrisiran Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 54: Eastern Europe, Vutrisiran Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 55: Eastern Europe, Vutrisiran Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 56: Russia, Vutrisiran Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 57: Russia, Vutrisiran Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 58: Russia, Vutrisiran Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 59: North America, Vutrisiran Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 60: North America, Vutrisiran Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 61: North America, Vutrisiran Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 62: USA, Vutrisiran Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 63: USA, Vutrisiran Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 64: USA, Vutrisiran Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 65: Canada, Vutrisiran Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 66: Canada, Vutrisiran Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 67: Canada, Vutrisiran Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 68: South America, Vutrisiran Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 69: South America, Vutrisiran Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 70: South America, Vutrisiran Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 71: Brazil, Vutrisiran Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 72: Brazil, Vutrisiran Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 73: Brazil, Vutrisiran Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 74: Middle East, Vutrisiran Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 75: Middle East, Vutrisiran Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 76: Middle East, Vutrisiran Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 77: Africa, Vutrisiran Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 78: Africa, Vutrisiran Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 79: Africa, Vutrisiran Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 80: Alnylam Pharmaceuticals Inc. Financial Performance

Latest Cell Therapy Market Growth Study 2022-2026 By The Business Research Company

Global Gene Therapy Market 2022 – Market Opportunities And Strategies

The Microbiome Market Share, Market Size, And Growth Rate 2022

Latest TNF Alpha Inhibitors Market Growth Study 2022-2026 By The Business Research Company

The Business Research Company offers the plasma fractionation market research report 2022 with industry size, share, segments and market growth

The Business Research Company offers the stem cell therapy market research report 2022 with industry size, share, segments and market growth

The Business Research Company offers the regenerative medicine for cartilage market research report 2022 with industry size, share, segments and market growth

Hereditary Cancer Testing Global Market Report 2025 – By Test Type( Multi Panel Test, Single-site Genetic Test), By Indication( Breast Cancer, Ovarian Cancer, Colorectal Cancer, Other Indications), By End user( Hospital, Clinics, Diagnostic Centers) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Hereditary Angioedema Therapeutics Global Market Report 2025 – By Drug Class (C1 Esterase Inhibitor, Selective Bradykinin B2 Receptor Antagonist, Kallikrein Inhibitor, Other Drug Classes), By Route of Administration (Intravenous, Subcutaneous, Oral), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Other Distribution Channels), By Application (Prophylaxis, On-demand) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Hereditary Breast and Ovarian Cancer Syndrome Treatment Global Market Report 2025 – By Treatment (Hormonal Therapy, Chemoprevention, Genetic Counselling, Medication, Other Treatments), By Diagnosis (Genetic Testing, Magnetic Resonance Imaging (MRI), Mammography, Other Diagnosis), By Route Of Administration (Oral, Parenteral, Other Routes Of Administration), By End-User (Hospitals, Specialty Clinics, Homecare, Other End-Users) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Nerve Repair And Regenerative Global Market Report 2025 – By Product (Biomaterials, Neurostimulation And Neuromodulation Devices), By Application (Direct Nerve Repair/Neurorrhaphy, Nerve Grafting, Stem Cell Therapy, Neurostimulation And Neuromodulation Surgeries, Other Applications), By End-Users (Hospitals And Clinics, Ambulatory Surgical Centers (ASCs), Research And Academic Institutions, Specialty Clinics, Other End-Users) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Optic Nerve Disorders Treatment Global Market Report 2025 – By Treatment Type (Steroidal Therapy, Immunomodulators therapy, Other Treatment Types), By Indication (Glaucoma, Optic Neuritis, Optic Neuropathy, Congenital Optic Atrophy, Other Indications), By End User (Hospitals, Ambulatory Surgery Centers, Clinics, Other End Users) – Market Size, Trends, And Global Forecast 2025-2034

View Report

C-Reactive Protein Testing Global Market Report 2025 – By Assay Type (Enzyme-Linked Immunosorbent Assay (ELISA), Chemiluminescence Immunoassay (CLIA), Immunoturbidimetric Assays), By Application (Diabetes, Rheumatoid Arthritis, Cardiovascular Disease, Inflammatory Bowel Disease, Cancer, Other Applications ), By End Use (Clinics, Hospitals, Diagnostic Laboratories) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Egg Protein Powder Global Market Report 2025 – By Type (Whole Egg Powder, Egg Yolk Powder, Egg White Powder), By Form (Solid, Liquid), By Application (Dietary Supplements, Bakery Products, Meat Products, Ice Creams, Other Applications) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Protein Supplements Global Market Report 2025 – By Type (Protein Powder, Protein Bar, Ready to Drink), By Source (Plant-based, Animal-based), By Raw Material (Casein Protein Supplements, Whey Protein Supplements, Egg Protein Supplements, MPC Protein Supplements, Soy Protein Supplements), By Distribution Channel (Supermarkets & Hypermarkets, Online Stores, Drug Stores) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Frequently Asked Questions

What is the definition of the Vutrisiran market?

How will the Vutrisiran market drivers and restraints affect the market dynamics? What forces will shape the Vutrisiran industry going forward?

The Vutrisiran market major growth driver - Rising Research And Development (R&D) Investments Fuel Growth Of The Market. For further insights on the Vutrisiran market, request a sample here

What is the forecast market size or the forecast market value of the Vutrisiran market?

The Vutrisiran market size has grown strongly in recent years. The vutrisiran market size has grown rapidly in recent years. It will grow from $0.60 billion in 2024 to $0.68 billion in 2025 at a compound annual growth rate (CAGR) of 12.8%. The growth in the historic period can be attributed to increasing awareness of hereditary transthyretin amyloidosis, rising clinical trials, increasing healthcare spending, rising patient preference for non-invasive administration methods, and rising genetic disorders. The vutrisiran market size is expected to see rapid growth in the next few years. It will grow to $1.08 billion in 2029 at a compound annual growth rate (CAGR) of 12.4%. The growth in the forecast period can be attributed to increasing healthcare availability, rising prevalence of chronic diseases, increasing investment in research and development, growing focus on personalized medicine, and rising awareness of disease. Major trends in the forecast period include development in combination therapy, adoption of targeted therapy, advancement in personalized medicine, development in digital health technologies, and advancements in biotechnology. For further insights on the Vutrisiran market, request a sample here

How is the Vutrisiran market segmented?

The vutrisiran market covered in this report is segmented –
1) By Drug Class: Antisense Oligonucleotide, Nucleic Acids, Nucleotide, Nucleoside, Other Drug Classes
2) By Route Of Administration: Oral, Injectable, Subcutaneous
3) By Patient Demographics: Pediatric, Adult, Geriatric
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channels

Subsegments:
1) By Antisense Oligonucleotide: Single-Stranded Antisense Oligonucleotides, Double-Stranded Antisense Oligonucleotides
2) By Nucleic Acids: DNA-based Nucleic Acids, RNA-based Nucleic Acids
3) By Nucleotide: Purine Nucleotides, Pyrimidine Nucleotides
4) By Nucleoside: Purine Nucleosides, Pyrimidine Nucleosides
5) By Other Drug Classes: Peptide-Based Drugs, Protein Therapeutics For further insights on the Vutrisiran market, request a sample here

Which region has the largest share of the Vutrisiran market? What are the other regions covered in the report?

Who are the major players in the Vutrisiran market?

Major companies operating in the vutrisiran market are Alnylam Pharmaceuticals Inc . For further insights on the Vutrisiran market, request a sample here.

What are the key trends in the Vutrisiran market?

Major trends in the Vutrisiran market include Advancements In Subcutaneous RNAi Therapeutics For hATTR Amyloidosis Treatment. For further insights on the Vutrisiran market, request a sample here.

What are the major opportunities in the Vutrisiran market? What are the strategies for the Vutrisiran market?

For detailed insights on the major opportunities and strategies in the Vutrisiran market, request a sample here.

How does the Vutrisiran market relate to the overall economy and other similar markets?

For detailed insights on the key dynamics influencing the Vutrisiran market growth and SWOT analysis of the Vutrisiran industry, request a sample here.

For detailed insights on Vutrisiran's relation to the overall economy and other similar markets,

What are the latest mergers and acquisitions in the Vutrisiran industry? request a sample here.

For detailed insights on the mergers and acquisitions in the Vutrisiran industry,

What are the key dynamics influencing the Vutrisiran market growth? SWOT analysis of the Vutrisiran market. request a sample here.